Determining which patients are most likely to benefit from BRAF-targeted therapies was the topic of a recent review in ASCO Educational Book by Anna C. Pavlick, DO, MBA, and colleagues at New York University Perlmutter Cancer Center, who noted that while research in this area is rapidly progressing, the answer to this important question is still unclear, as nearly 50% of melanoma patients have a BRAF mutation.

Learn more by clicking here.